You are here
CLS Exhibits Thermal Therapy Laser Ablation System at AdMeTech Annual Conference
Unique Non-Cooled Fiber Technology Optimizes Heat Distribution, Eliminates External Cooling, Reduces Procedure Times
FRAMINGHAM, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS Americas) a subsidiary of CLS AB in Lund, Sweden, will be exhibiting its TRANBERG®|Thermal Therapy System and single-use accessories at the AdMeTech Annual Conference this August 3-5, 2018. This year’s theme is, “PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER.”
”CLS is pleased to participate in this year’s AdMeTech conference. Our TRANBERG Thermal Therapy System is well suited to support this years theme of Precision Diagnosis and Treatment of Prostate Cancer,” stated Alan Weinberg, General Manager of CLS Americas.
The CLS Thermal Therapy System is designed and optimized to be utilized in conjunction with MRI-guided laser ablation for prostate treatment. It is currently in clinical use at several well known clinical centers in the United States and at other hospitals in the U.S., Sweden, and other European countries. Clinical trials are underway at Toronto General Hospital. CLS received FDA-clearance for its single-use TRANBERG®|Laser Applicator Non-cooled diffusor fiber in early 2017.
About the CLS TRANBERG Thermal Therapy System
CLS developed the system for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desk-top mobile laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories.
Unique, Non-Cooled, Diffusing Fiber Technology
CLS utilizes unique, non-cooled, diffusing laser fiber technology to optimize heat distribution in tissue while eliminating the need for external cooling. The system also includes features designed to improve workflow and reduce procedure times.
About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially-designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se.
The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).
CONTACT: Media Contact TopSpin Communications Joe Waldygo P: 480-363-8774 E: email@example.com Company Contact CLS Americas, Inc. Alan Weinberg, General Manager P: 508-620-4521 E: firstname.lastname@example.org